GSK CEO says looking at Pfizer consumer business, but not a priority

Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire."At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco.Despite her consumer products background, Walmsley repeatedly said that the co